Genevation Ltd

Developing personalized mRNA cancer vaccines using AI to accelerate discovery and production.

Cover Block

Open sources

Field	Value
Name	Genevation Ltd
Tagline	Developing personalized mRNA cancer vaccines using AI to accelerate discovery and production.
Headquarters	Stevenage, UK [Stevenage Bioscience Catalyst, January 2026]
Founded	2022 [Endole, retrieved 2026]
Stage	Pre-Seed [VCBacked, February 2024]
Business Model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-seed
Total Disclosed	~$505,000 [VCBacked, February 2024]

What an Investor Needs First

PUBLIC Genevation Ltd is a UK pre-clinical biotech developing personalized mRNA cancer vaccines, and it merits investor attention now because public evidence shows an early financing event and a recent admission to Stevenage Bioscience Catalyst's Lab Hotel, a useful third-party signal for a company still light on independent coverage [VCBacked, February 2024] [Stevenage Bioscience Catalyst, January 2026]. The company was incorporated in July 2022 and presents itself as building an AI-driven, cell-free platform that selects patient-specific neoantigens and aims to move from biopsy to individualized vaccine in roughly two weeks, versus about eight weeks for conventional approaches according to its EuroQuity profile and LinkedIn description [Endole, retrieved 2026] [EuroQuity, retrieved 2026] [LinkedIn, retrieved 2026].

The technical pitch is straightforward: use genomics, immuno-oncology, in-vitro transcription, and mRNA workflows to design therapeutic and prophylactic vaccine candidates tailored to individual tumors, with an initial focus on lung, colon, and skin cancers [Genevation, retrieved 2026] [MTEC] [Genevation, retrieved 2026]. That is an ambitious proposition in a crowded and capital-intensive category, so the distinguishing claim is less the use of mRNA itself than the promised speed and the cell-free manufacturing approach, both of which remain company-stated rather than independently validated in public sources [EuroQuity, retrieved 2026] [Genevation, retrieved 2026].

Leadership appears to center on founder and CEO Dr Prasun Chakraborty, whom the company and multiple public profiles identify as Genevation's founder, with prior experience in RNA biology, cancer biology, and related research settings [Genevation, retrieved 2026] [NextGen Biomed - Look Back, 2025] [Genevation LTD | LinkedIn, retrieved 2026]. The public record is directionally supportive on his scientific background, but it is less clean on broader team presentation, and investors will want direct clarification on leadership roles and execution capacity as the company moves from platform narrative toward preclinical proof points [Genevation, retrieved 2026] [HighGround, retrieved 2026].

On financing, the clearest disclosed datapoint is a reported $505,000 pre-seed round in February 2024, with Oxford Technology Management identified as an investor; the business model is best understood today as B2B, likely oriented toward research, development, and eventual clinical partnerships rather than direct patient sales [VCBacked, February 2024] [Crunchbase, retrieved 2026]. Over the next 12 to 18 months, the watch items are concrete rather than thematic: independent validation of the two-week workflow claim, clearer evidence of collaborations beyond profile-page references, and any preclinical or translational milestones that show the platform can move from concept to reproducible oncology data [LinkedIn, retrieved 2026] [Prasun Chakraborty on LinkedIn, December 2023] [Stevenage Bioscience Catalyst, January 2026].

Partially corroborated -- Relies on one independently reported funding database entry, one named third-party ecosystem announcement, and several company or profile-page claims that are only partially corroborated.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed, total disclosed about $505,000

Inside the Company

PUBLIC Genevation Ltd is a UK biotechnology company developing personalized mRNA cancer vaccines, with its public materials centering on an AI-driven, cell-free platform for patient-specific oncology applications [Genevation, retrieved 2026]. Corporate records and company profiles place the business in Stevenage, UK, and show incorporation on 26 July 2022 under the legal name Genevation Ltd [Endole, retrieved 2026] [Crunchbase, retrieved 2026]. The basic company profile is straightforward, but most operating detail in the public record still comes from the company itself rather than third-party reporting [Genevation, retrieved 2026] [Crunchbase, retrieved 2026].

The chronology is still short. After incorporation in mid-2022, the clearest disclosed financing marker is a pre-seed round of $505,000 reported in February 2024 [Crunchbase, retrieved 2026]. More recently, Genevation was listed by Stevenage Bioscience Catalyst as a Lab Hotel company, giving it a visible presence within the UK life sciences ecosystem in Stevenage and indicating access to laboratory and office support at that site [Stevenage Bioscience Catalyst, January 2026] [Genevation, retrieved 2026].

Public founder identification is somewhat uneven across sources. Genevation's website identifies Dr Prasun Chakraborty as Founder and CEO, while external profile pages also associate him with the company as founder and chief executive [Genevation, retrieved 2026] [Crunchbase, retrieved 2026]. Other team references appear in broader web profiles, but the core point supported by the company site and startup databases is that Genevation remains an early-stage, founder-led entity with limited independently reported operating history [Genevation, retrieved 2026] [Crunchbase, retrieved 2026].

Partially corroborated -- Core incorporation and company profile details are supported by Endole and Crunchbase, while leadership and product framing rely partly on the company website.

Under the Hood

MIXED

Genevation is presenting a narrow but ambitious technical claim: a personalized cancer vaccine platform built around mRNA, genomics, immuno-oncology, and in vitro transcription, with AI used to help identify patient-specific tumor antigens [Genevation, retrieved 2026] [EuroQuity, retrieved 2026]. In plain English, the company says it is designing individualized cancer vaccines rather than a one-size-fits-all product, and it describes the platform as cell-free and AI-driven [Genevation, retrieved 2026]. The public record does not yet extend to a verified product demo, clinical data release, or third-party technical validation, so the current description rests mainly on company-authored materials and profile pages [Genevation, retrieved 2026] [EuroQuity, retrieved 2026].

The most specific operational assertion is speed. Genevation states that its process from biopsy to vaccine is intended to take about two weeks, versus roughly eight weeks for conventional approaches, using AI-mediated neoantigen selection and manufacturing for personalized cancer vaccines [EuroQuity, retrieved 2026] [LinkedIn, retrieved 2026]. It also says the initial disease focus includes lung, colon, and skin cancers, with expansion to other cancer types planned, and that both therapeutic and prophylactic mRNA vaccine candidates are being developed from patient-specific neoantigens [Genevation, retrieved 2026] [MTEC, retrieved 2026].

A separate public signal is that Prasun Chakraborty has described the company as developing personalized RNA-based cancer vaccines in collaboration with the University of Cambridge and Illumina [Prasun Chakraborty on LinkedIn, December 2023]. That is directionally helpful because it points to an external scientific ecosystem, but the nature of those collaborations is not spelled out in the cited material, and no public technical documentation in the provided sources establishes how far the platform has progressed beyond pre-clinical development [Prasun Chakraborty on LinkedIn, December 2023] [Stevenage Bioscience Catalyst, January 2026].

Claim stands unchecked -- This section relies primarily on company-authored claims, with partial support from LinkedIn and profile pages but no independent technical validation or verified demo in the cited public record.

Market Research

Open sources The market matters now because personalized oncology is moving from a research ambition toward a manufacturing and logistics problem, and Genevation is positioned on that transition rather than on broad platform discovery alone [MTEC, retrieved 2026] [EuroQuity, retrieved 2026].

The public record does not support a clean TAM, SAM, and SOM build for Genevation specifically, and there is no named third-party market report in the source set with numeric market sizing for personalized mRNA cancer vaccines. What the sources do show is the category Genevation is trying to enter: therapeutic and prophylactic mRNA vaccine candidates designed from patient-specific neoantigens, with an intended biopsy-to-vaccine cycle of roughly two weeks according to company and profile materials [MTEC, retrieved 2026] [LinkedIn, retrieved 2026] [EuroQuity, retrieved 2026]. In practical terms, that places the company at the intersection of oncology therapeutics, precision medicine, and contract or internalized nucleic-acid manufacturing, rather than in a conventional software market [Genevation, retrieved 2026] [MTEC, retrieved 2026].

Demand drivers in the cited material are straightforward. Genevation's stated wedge is speed and personalization: AI-mediated neoantigen selection, a cell-free mRNA approach, and individualized vaccines intended for cancers including lung, colon, and skin cancer [Genevation, retrieved 2026] [EuroQuity, retrieved 2026]. If that workflow proves clinically and operationally credible, it speaks to a real bottleneck in personalized cancer vaccines, where patient-specific design only matters if manufacturing can keep pace with treatment windows; that remains an inference from the product framing, not an observed market outcome [EuroQuity, retrieved 2026] [LinkedIn, retrieved 2026].

The adjacent markets are easier to identify than the core one. The company is effectively touching three spend pools: precision oncology diagnostics and neoantigen identification, mRNA therapeutic development, and specialized lab infrastructure for early-stage translational biotech [Genevation, retrieved 2026] [Stevenage Bioscience Catalyst, January 2026]. The Stevenage Bioscience Catalyst placement is modest in commercial terms, but it does signal that Genevation is operating inside the UK translational-biotech infrastructure stack rather than as a purely virtual drug-design startup [Stevenage Bioscience Catalyst, January 2026].

Regulation and macro conditions cut both ways. On the supportive side, oncology remains a high-priority therapeutic area, and mRNA is now a more familiar modality to funders, researchers, and regulators than it was prior to the pandemic, which likely lowers the educational burden for new entrants; that point is an analytical inference rather than a directly cited market statistic. On the constraining side, personalized cancer vaccines face long validation cycles, manufacturing scrutiny, and evidence thresholds that are materially higher than for software-led healthtech, and the available sources do not show clinical deployment, trial data, or named pharmaceutical partnerships for Genevation yet [Stevenage Bioscience Catalyst, January 2026] [Genevation, retrieved 2026].

Market lens	Public evidence	Implication for Genevation
Personalized neoantigen vaccines	Genevation and third-party profiles describe patient-specific mRNA cancer vaccines and neoantigen-based design [Genevation, retrieved 2026] [MTEC, retrieved 2026]	Supports a focused precision-oncology positioning rather than a general mRNA platform claim
Manufacturing speed as a market wedge	Company and profile sources cite an intended two-week biopsy-to-vaccine timeline [EuroQuity, retrieved 2026] [LinkedIn, retrieved 2026]	Suggests the commercial argument may rest on turnaround time as much as on antigen selection
Translational biotech infrastructure	Genevation received Lab Hotel space and support at Stevenage Bioscience Catalyst [Stevenage Bioscience Catalyst, January 2026]	Indicates fit with early UK biotech infrastructure, but not customer validation

The market picture is credible in direction but still thin in quantified external evidence. For investors, the main read-through is that Genevation is addressing a real oncology workflow constraint, yet the current public record supports category relevance more clearly than market share potential.

Partially corroborated -- Section relies on one independent named publisher for ecosystem context, plus company and profile sources for product-market framing.

Competition and Substitutes

MIXED Genevation is positioning itself against established personalized cancer vaccine developers on speed and manufacturing design, but the public record is thin enough that the competitive case still rests more on stated architecture than on demonstrated clinical or commercial proof [Genevation, retrieved 2026] [EuroQuity, retrieved 2026] [MTEC, retrieved 2026].

The competitive map is clearest at the category level even though the source set does not name direct peers. Genevation sits in personalized oncology vaccines, a segment that already includes larger and better-capitalized biotech programs pursuing neoantigen selection, individualized manufacturing, and mRNA delivery, while adjacent substitutes include checkpoint inhibitors, cell therapies, and off-the-shelf immuno-oncology approaches that avoid bespoke production for each patient [Genevation, retrieved 2026] [MTEC, retrieved 2026]. Within that frame, incumbents tend to have the advantage in clinical infrastructure, regulatory experience, and financing depth, while newer entrants try to compress biopsy-to-vaccine timelines or reduce manufacturing complexity. Genevation's own materials emphasize a two-week process and a cell-free, AI-driven platform, which suggests its challenge is not to prove that personalized vaccines matter, but to show that its workflow is materially faster or cheaper in a way that survives clinical and regulatory scrutiny [EuroQuity, retrieved 2026] [LinkedIn, retrieved 2026].

The company's edge, as publicly presented, is narrow but legible. Management describes an AI-mediated neoantigen selection process paired with cell-free mRNA vaccine production, and separately points to collaboration with the University of Cambridge and Illumina, which, if sustained and formalized, could matter because data interpretation and manufacturing turn time are two of the hardest bottlenecks in individualized cancer vaccines [Prasun Chakraborty on LinkedIn, December 2023] [EuroQuity, retrieved 2026] [LinkedIn, retrieved 2026]. The difficulty is durability. A claimed two-week cycle is potentially meaningful, but today it appears in company-controlled or profile-style sources rather than independent validation, so the edge looks perishable until the company shows reproducible technical data, partner validation, or early clinical evidence [EuroQuity, retrieved 2026] [Genevation, retrieved 2026].

The exposure is more straightforward. Personalized cancer vaccines are capital-intensive, science-intensive, and usually validated over long development cycles, while Genevation's disclosed funding is only a reported $505,000 pre-seed round in February 2024, with Oxford Technology Management identified as an investor in the broader source set [VCBacked, February 2024] [Crunchbase, retrieved 2026]. That leaves the company vulnerable to any named competitor with deeper trial budgets, owned clinical channels, or established GMP manufacturing, even if Genevation's discovery layer is directionally promising. It is also exposed to adjacent modalities that can reach oncologists through existing treatment pathways without requiring a fully individualized production process, which means speed alone may not be enough unless it is paired with strong efficacy and operational reliability [Genevation, retrieved 2026] [Stevenage Bioscience Catalyst, January 2026].

The most plausible 18-month scenario is a sorting event around proof, not messaging. Winner if X: Genevation, if it can convert its current proposition into externally verified evidence that the biopsy-to-vaccine workflow can consistently run near the stated two-week target and attract research or development partners beyond incubator support [EuroQuity, retrieved 2026] [Stevenage Bioscience Catalyst, January 2026]. Loser if Y: smaller preclinical entrants in personalized mRNA oncology, including Genevation, if fundraising remains constrained and larger named programs in the category continue to absorb the clinical talent, manufacturing capacity, and regulatory attention that early companies need to compete. Public evidence today is enough to establish the lane, but not enough to rank Genevation convincingly within it.

Claim stands unchecked -- This section relies mainly on company-controlled materials and profile pages for product positioning, with limited independent confirmation beyond Stevenage Bioscience Catalyst and database-reported funding [Genevation, retrieved 2026] [EuroQuity, retrieved 2026] [Stevenage Bioscience Catalyst, January 2026] [VCBacked, February 2024].

Opportunity

Open sources If Genevation can compress personalized cancer-vaccine design and manufacturing from a multimonth bespoke workflow into something measured in weeks, the prize is not a single drug asset but a repeatable oncology platform that could matter across multiple solid-tumor programs [EuroQuity, retrieved 2026] [LinkedIn, retrieved 2026] [MTEC, retrieved 2026].

The clearest upside case is straightforward. Genevation is trying to build an AI-driven, cell-free mRNA vaccine platform for patient-specific cancer treatment, and the public materials are at least directionally consistent on the core claim: individualized neoantigen selection, RNA-based design, and an intended biopsy-to-vaccine timeline of roughly two weeks [Genevation, retrieved 2026] [EuroQuity, retrieved 2026] [LinkedIn, retrieved 2026]. In biotech terms, that matters because speed is not just a convenience variable. For personalized oncology, faster antigen identification and faster manufacturing could widen clinical usability, improve partner economics, and make the platform more attractive to hospitals, research centers, and drug developers that do not want to build this workflow in-house [MTEC, retrieved 2026] [Stevenage Bioscience Catalyst, January 2026].

The reachability case remains early, but not entirely abstract. Genevation has been incorporated since July 2022, has reported pre-seed financing of $505,000 in February 2024, and has secured space in Stevenage Bioscience Catalyst's Lab Hotel, which provides laboratory accommodation and support infrastructure [Endole, retrieved 2026] [VCBacked, February 2024] [Stevenage Bioscience Catalyst, January 2026]. That does not establish clinical validation, but it does show a company moving from concept toward an operating environment where assay development, translational work, and partner discussions can happen.

Scenario	What happens	Catalyst	Why it's plausible
Fast-turnaround oncology platform	Genevation becomes a development partner for research hospitals and biotech companies that need personalized cancer-vaccine design and small-batch manufacturing on a shorter timeline than conventional workflows	Demonstration that the biopsy-to-vaccine process can reliably run in about two weeks in early translational or pilot settings	The company has repeatedly described a two-week workflow and an AI-mediated neoantigen-selection process across its website, LinkedIn presence, and EuroQuity profile [Genevation, retrieved 2026] [LinkedIn, retrieved 2026] [EuroQuity, retrieved 2026]
Neoantigen engine for multiple tumor programs	The company evolves from one cancer application into a broader platform used across lung, colon, skin, and additional tumor types	A research collaboration or validation package that shows the same platform can generate candidates across more than one solid-tumor setting	Genevation states it is initially focused on lung, colon, and skin cancers, with plans to expand further, which supports a platform framing rather than a single-indication framing [Genevation, retrieved 2026]
UK to cross-border R&D node	Genevation uses the UK base and external research relationships to become an early cross-border precision-oncology development node	Formalization of collaborations around sequencing, antigen discovery, or process development	Public materials tie the company to Stevenage Bioscience Catalyst and describe work in collaboration with the University of Cambridge and Illumina, although the latter remains only partially corroborated in public sources [Stevenage Bioscience Catalyst, January 2026] [Prasun Chakraborty on LinkedIn, December 2023]

The compounding mechanism, if it works, would come from learning effects rather than classic consumer network effects. Each additional patient or partner program could sharpen neoantigen-selection models, improve manufacturing reproducibility, and build a library of process know-how around turnaround time, yield, and tumor-specific response hypotheses [LinkedIn, retrieved 2026] [MTEC, retrieved 2026]. In that model, one successful deployment does not just add revenue, it reduces friction for the next deployment. The early signs are still modest, but the ingredients of that flywheel are visible in the company's own positioning: AI-mediated selection, cell-free mRNA production, and a stated focus on repeatable speed as the product wedge [Genevation, retrieved 2026] [EuroQuity, retrieved 2026].

The size of the win is best framed conditionally because no market-sizing data in the source set is strong enough to support a hard revenue model. Still, if Genevation were to prove that a two-week personalized vaccine workflow can be operationalized across multiple oncology programs, the company could plausibly become a strategic platform target for larger biotech or life-science infrastructure players rather than remain a single-asset startup (scenario, not a forecast) [MTEC, retrieved 2026] [Stevenage Bioscience Catalyst, January 2026]. That outcome would depend first on technical validation, then on repeatability, and only later on commercial scale, but the upside case is large precisely because the company is attempting to compress one of the slowest and least standardized parts of precision oncology into a serviceable platform layer [Genevation, retrieved 2026] [EuroQuity, retrieved 2026].

Claim stands unchecked -- This section relies materially on company statements and directory-style profiles, with limited independent corroboration beyond incorporation, the reported pre-seed round, and Stevenage Bioscience Catalyst participation.

Sources